Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745107 | 1.00 | TRPV1 (0.49) | TRPV1CES2CES1PTPN1GSK3B | |
| SCHEMBL1745106 | 1.00 | TRPV1 (0.49) | TRPV1CES2CES1PTPN1GSK3B | |
| SCHEMBL1245267 | 0.85 | TPMT (0.41) | GSK3B | |
| SCHEMBL1746426 | 0.85 | CES2 (0.45) | CES2SRD5A2MAOB | |
| SCHEMBL1746430 | 0.85 | CES2 (0.45) | CES2SRD5A2MAOB | |
| SCHEMBL3946752 | 0.84 | CYP1A1 (0.45) | CES2CES1PTPN1GSK3BSRD5A2 | |
| SCHEMBL3946748 | 0.84 | CYP1A1 (0.45) | CES2CES1PTPN1GSK3BSRD5A2 | |
| SCHEMBL1746899 | 0.83 | APP (0.42) | SRD5A2 | |
| SCHEMBL1746901 | 0.83 | APP (0.42) | SRD5A2 | |
| SCHEMBL1746518 | 0.83 | GSK3B (0.43) | TRPV1CES2CES1PTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | disclosed |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200215073-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC | 2020-07-09 | — | — | US | disclosed |
| US-10471066-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180071304-A1 | Phenoxy Acetic Acids and Phenyl Propionic Acids as PPAR Delta Agonists | HIGH POINT PHARMACEUTICALS, LLC | 2018-03-15 | — | — | US | disclosed |
| US-9855274-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170216303-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC | 2017-08-03 | — | — | US | disclosed |
| US-9663481-B2 | Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists | VTV THERAPEUTICS LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140024645-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8551993-B2 | Phenoxy acetic acids as PPAR delta activators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130102610-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-8362016-B2 | Phenyl propionic acids as PPAR delta activators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2386540-A1 | Novel compounds, their preparation and use | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-7943613-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090093484-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | VTVX HOLDINGS II LLC | 2009-04-09 | — | — | US | disclosed |
| EP-1979311-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471066-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | PPARG, PPARA, PPARD | TRPV1 1367/4885CES2 1752/4885CES1 710/4885 |
| US-20090093484-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | TRPV1 515/4885CES2 1800/4885CES1 272/4885 |
| US-20170216303-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | TRPV1 1496/4885CES2 2044/4885CES1 631/4885 |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | PPARG, PPARA, PPARD | TRPV1 1367/4885CES2 1752/4885CES1 710/4885 |
| US-20180071304-A1 | Phenoxy Acetic Acids and Phenyl Propionic Acids as PPAR Delta Agonists | PPARG, PPARA, PPARD | TRPV1 1367/4885CES2 1752/4885CES1 710/4885 |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | TRPV1 897/4885CES2 1515/4885CES1 386/4885 |
| US-20200215073-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | TRPV1 1367/4885CES2 1752/4885CES1 710/4885 |
| US-20130102610-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | TRPV1 897/4885CES2 1515/4885CES1 386/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | TRPV1 1367/4885CES2 1752/4885CES1 710/4885 |
| US-20140024645-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | TRPV1 1496/4885CES2 2044/4885CES1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.